Myopia

IVMED-85 is a preservative-free, nonatropine daily drop that slows myopia progression by strengthening scleral and corneal collagen crosslinks via LOX activation.

Increases in the doses of atropine were most common following the pandemic and especially among patients for whom therapy was initiated with the 0.01% dose.

New data from North American and Chinese clinical trials reinforce the safety, efficacy, and durability of DOT lenses in slowing pediatric myopia progression, without evidence of rebound.

At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.

After treatment cessation, eye growth returned to age-expected levels and the accumulated myopia control treatment gains were retained over the following 12 months after treatment was ceased.

The CATHAY trial evaluated 186 myopic children, 6 to 13 years old at initiation, across 5 hospitals.

Eva Kim, MD, offers valuable insights into why EVO ICL is becoming a compelling alternative to traditional corneal procedures like LASIK.

In honor of the Myopia Management Navigator’s 1-year anniversary, Dr Tucker shares clinical insights, practical tips, and business opportunities for optometrists looking to expand their scope and elevate patient care through evidence-based myopia management.

Researchers found that repeated therapy using low-level red light (RLRL) is a potential intervention to control myopia progression in children.

According to a press release, Myatro XL is the first 0.05% atropine eye drop for pediatric myopia control. It will be commercially available in India in July 2025.

How studies into myopia management can increase access to vision care.

Following a discussion on low-dose atropine, Paul Karpecki, OD, FAAO, shares his views on what the future of myopia management looks like.

Dr Rachelle Lin highlights the urgent need for early intervention in childhood myopia, discusses associated retinal and systemic risks, and emphasizes the long-term impact of axial length control in reducing serious ocular complications.

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary end point for slowing pediatric myopia progression.

In April 2021, WCO partnered with CooperVision to introduce its myopia management standard of care, defining evidence-based standard of care comprising of mitigation, measurement, and management.

The 6th World Congress of Optometry will be held during Saudi Society of Optometry’s 11th Optometry Conference and Exhibition.

The system aids in the orthokeratology lens design process by syncing directly with topographers to create precise lens designs for the treatment of myopia in the matter of seconds.

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

The upgraded Myopia Software Package offers comprehensive screening, ortho-k fitting, and myopia management in one device.

The study evaluated 13 teenagers and young adults who had high myopia (−6.50 to −9.25 D).

Visual acuity remains an important indication of ocular and visual health.

The 2025 Myopia Research Grant will comprise of 3 awards of $500,000 each.

From eye drops to novel treatments, it’s time to assess all options for improving patients’ visual acuity.